BARCELONA, Spain and CAMBRIDGE, Mass., July 21, 2015 /PRNewswire/ -- Oryzon Genomics, an epigenetics-based biotechnology company focused on developing therapeutics in oncology and neurodegenerative diseases, will present this week their last results on its late preclinical Alzheimer's drug ORY-2001 at the 2015 Alzheimer's Association International Conference in Washington, DC.
The company will present this data on Wednesday the 22nd at the Hall D of the Walter E. Washington Convention center with a poster entitled: Ory-2001 a Dual LSD1/MAO-B Inhibitor Prevents the Development of the Memory Deficit in Samp-8 Mice. The company is developing ORY-2001, a dual LSD1-MAOB inhibitor, as a new therapeutic approach for Alzheimer's disease (AD). The molecule is expected to start Phase I early next year.
Oryzon's drug candidate targets the enzyme LSD1, a histone demethylase which plays a role in regulating the expression of crucial genes that neurons need to stay alive. LSD1 is able to switch the expression of those genes on and off in the neurons in response to age, insults and environmental conditions. LSD1 also regulates the expression of genes involved in the progression of AD and other neurological disorders, such as Parkinson´s and Huntington's diseases.
Founded in 2000 in Barcelona, Spain, Oryzon (www.oryzon.com) is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics with one of the strongest portfolio in the field. Its LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one to enter clinical trials by the beginning of 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other histone demethylases and histone methyltransferases. The company has also a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. In October 2014, ORYZON announced opening of U.S. operations in Cambridge, Massachusetts through its U.S. affiliate, Oryzon Corp.
President & CEO
Executive V.P. and Global CFO
W: +1 617-444-8786
Business Development Officer